Regula Launches Full Support for Digital Travel Credentials in Latest Software Update
15.1.2025 08:00:00 CET | Business Wire | Press release
Regula, a global developer of forensic devices and identity verification solutions, has updated its Regula Document Reader SDK. Now, the software fully supports the new Digital Travel Credential (DTC) format, aligned with the International Civil Aviation Organization (ICAO) standards. This enhancement enables governments, airlines, and border control authorities worldwide to process travel documents with unmatched security, efficiency, and ease—whether on-site or remotely.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250115990355/en/

With Regula Document Reader SDK, travelers can create their own digital credentials by extracting a Virtual Component (DTC-VC) from a physical electronic identity document like ePassport. (Graphic: Regula)
The DTC is a secure digital solution that streamlines travel experiences. It consolidates key personal information into a single virtual document that travelers can store on their mobile devices or upload to their digital wallets and share whenever needed. The main goal of the DTC is to facilitate clearance procedures during travel and ensure that people are eligible to enter their destination before they board a flight.
The ICAO has defined three types of DTC, each offering varying levels of convenience and security for travelers.
- DTC Type 1 allows travelers to create their own digital credentials by extracting a Virtual Component (DTC-VC) from a physical electronic identity document, stored on their personal device. However, travelers must still carry the original document for identity verification.
- DTC Type 2, issued by authorities, combines a cryptographically linked Virtual Component (DTC-VC) and a Physical Component (DTC-PC). This format adds an extra layer of security while maintaining a connection to the physical document.
- DTC Type 3 represents the future of travel identification: a fully digital document issued directly by authorities. Unlike the other types, it eliminates the need for a physical ID, streamlining identity verification for a completely digital experience.
Now, with Regula Document Reader SDK, users can create and reprocess DTC-VC from ePassports, and verify it by passing DTC-VC data as input. Also, support for handling DTC-PC has been introduced. The updated Regula Document Reader SDK can:
- read the document’s RFID chip with a smartphone or passport reader and create DTC-VC;
- recognize, read, and verify DTC-VC with a smartphone, passport reader, or server;
- read DTC-PC with a smartphone or passport reader, parse its data, and verify it.
The updated Regula Document Reader SDK is equipped with advanced features that fully support DTC implementation.
- Trustworthy NFC verification. First and foremost, it provides trusted server-side NFC verification of the ID so it ensures accurate and trustworthy DTC-VC creation. Since all the data from the chip can be verified on a secure server, there is no need to question the reliability of the checks performed by a mobile device (which is prone to manipulation). Such an approach ensures that the virtual component of a traveler’s document is secure and taken from an authentic ID.
- Compliance with ICAO guidelines and technical reports. Regula Document Reader SDK not only verifies DTCs but also guarantees that each DTC fully complies with ICAO guidelines and technical reports. This makes Regula’s solution an indispensable tool for airlines and governments so they can be confident in the validity of travelers’ DTCs.
- Future-ready technology. In addition to supporting DTC-VC, Regula’s technology is fully compatible with handling DTC-PC. Looking further ahead, Regula is ready to process DTC Type 3, a digital passport that is expected in the next several years.
To facilitate the fast and smooth global application of DTCs, Regula Document Reader SDK relies on the most comprehensive identity document template database, which is owned and maintained by Regula. Currently, it contains more than 14,000 ID templates from 251 countries and territories, and it’s constantly growing.
Regula Document Reader SDK is designed for easy integration into third-party applications, allowing clients to incorporate this advanced DTC-ready technology seamlessly into their existing systems. With customizable options, businesses can adapt the solution to meet their unique operational requirements while providing end users with a secure, streamlined digital experience.
“We see that the world is rapidly moving to embrace digital IDs. According to the Forrester Consulting study commissioned by Regula earlier in 2024, nearly half of businesses around the world, 42%, are actively integrating digital IDs into their systems. For the Aviation sector, this rate is even higher: 50%. By ensuring full DTC support in the latest update of Regula Document Reader SDK, we are helping our clients to smoothly transition to the future of travel, where secure, digital-first solutions redefine the passenger experience,” says Ihar Kliashchou, Chief Technology Officer at Regula.
To learn more about the capabilities of the updated Regula Document Reader SDK, read the release documentation on Regula’s website.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the most comprehensive library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification. Learn more at www.regulaforensics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250115990355/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom